Experts Are Trying To Understand NDMA
High levels of NDMA, a known carcinogen, may be responsible for thousands of cancer deaths
Friday, July 31, 2020 - Up until a year ago, little attention was paid to a chemical called NDMA, "a highly toxic organic compound that, in specific quantities, has the potential to become carcinogenic. It is found most commonly in drinking water, and in low quantities in products such as curated meats, tobacco, and beer, according to LegalReader. NDMA is the acronym for N-nitrosodimethylamine , the chemical compound that expands from acceptable to dangerously high levels in heartburn and acid reflux medicines called ranitidine, better known by the brand name Zantac. Sanofi, the manufacturer of Zantac, is concerned with having lost a billion dollar per year market and are frantically trying to understand why the chemical impurities happened and how to fix the problem and get the drug back on the market. The damage, however, may already be done. Scientists at the FDA and elsewhere are less concerned about Sanofi's profits and are focused on the extent to which Zantac has caused stomach, bladder, intestinal, and many other forms of cancer. If NDMA is found to have been caused by high temperatures, its interaction with nitrates in the stomach, or at the overseas manufacturing source, the scope of the health crisis could be overwhelming, far overshadowing any virus pandemic we could experience. Over 15 million people per year were using Zantac before the company and then the FDA issued complete recalls of the product and ordered consumers to destroy unused portions of the product. Understanding NDMA is the first step in finding how it becomes so deadly.
The US Food and Drug Administration describes the substance as, "... a nitrosamine impurity called N-nitrosodimethylamine (NDMA). NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests," according to ABC News. David Light, the CEO of online drug testing pharmacy Valisure, the people that originally discovered NDMA's chemical breakdown, told ABC, "NDMA was the result of the formulation of the ranitidine molecule, which they think may break down when it is digested in the human body creating NDMA," and continued by saying, "Because of its (Zantac ranitidine) widespread use there's no acceptable cancer risk for a drug like this."
Thousands of individuals that have developed stomach, bladder, intestinal, and many other forms of cancer have filed lawsuits accusing Sanofi of failing to warn consumers of Zantac's cancer risks. If you have taken Zantac or another heartburn or acid reflux medicine regularly for over a year, you should see your doctor immediately. Zantac cancer has a multi-year latency period. You could be a victim of Sanofi's negligence and not even know you are sick. Hundreds of plaintiffs, represented by Zantac Cancer Lawyers on the state level, are being consolidated into Federal Court to be tried as one multi-district litigation. Attorneys representing Zantac cancer plaintiffs expect thousands of Zantac cancer victims to come forward to contact them in the weeks and months to come.
More Recent Heartburn MedicineLawsuit News:
- Zantac Cancer Trials Are In Discovery To Begin In October 2022 | 7/19/2022
- Zantac Cancer Lawsuits Could Hinge On The Validity of Ranitidine Testing Methods | 7/11/2022
- Zantac Cancer Bellwether Trials In California Could Set The Stage For A Global Settlement Offer | 7/5/2022
- The FDA Recommended Protein Pump Inhibitor Drugs Like Prilosec And Nexium That May Damage Health More Than Zantac | 6/23/2022
- Truck Drivers, Firefighters, and Police Officers May Have Taken More Zantac Than People In Other Occupations | 6/20/2022
- Scientists Are Expected To Confirm That Ranidine Causes Gastrointestinal Cancer With Slam Dunk Testimony | 6/9/2022
- Scientific Hearings Will Start This September To Interview Zantac Cancer Expert Witnesses | 5/19/2022
- A Whistleblower Scientist Working For A Chinese Company Thinks NDMA Contamination Started In China | 5/12/2022
- Valisure's String Of Stunning Success Casts Doubt On The FDAs Ability To Police The Health Care Market | 5/2/2022
- Zantac Testing Accusations Heat Up With FDA Investigation Of Online Prescription Drug Testing Lab | 4/25/2022
- Study Finds Ranitidine Degrades Into 10,000 Nanograms of NDMA When Introduced To Simulated Stomach Conditions | 4/6/2022
- Potential Zantac Expert Witnesses Are Being Questioned By Zantac Defense Attorneys | 3/31/2022
- The FDA Requires That Drug Companies Regularly Test Ranitidine And Other Drug For NDMA | 3/24/2022
- Update: Where The Zantac Cancer Multidistrict Litigation (MDL) Stands Today | 3/12/2022
- Zantac Cancer Plaintiffs Look To The First Trial In October In Alameda California | 3/11/2022
- Zantac Cancer Plaintiffs Have Until June 30 To Finalize Their Claim | 3/7/2022
- Zantac Bellwether Trials May Focus On Ranitidine Testing Methods That Could Cause NDMA To Accelerate | 3/1/2022
- Valisure LLC's Motivations And Ranitidine Testing Methods May Not Be Scrutinized Before Trial | 2/24/2022
- Zantac Lawsuits May Go To Trial In California In October Of This Year | 2/18/2022
- Sanofi's History Of Reprehensible Corporate Behavior May Bolster Zantac Cancer Lawsuits | 2/10/2022
Lawyers for Zantac Heartburn Medicine Lawsuits
OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.